Connect
MJA
MJA

Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care

Debbie A Quain, Mark W Parsons, Allan R Loudfoot, Neil J Spratt, Malcolm K Evans, Michelle L Russell, Angela T Royan, Andrea G Moore, Ferdinand Miteff, Carolyn J Hullick, John Attia, Patrick McElduff and Christopher R Levi
Med J Aust 2008; 189 (8): 429-433.
Published online: 20 October 2008

Abstract

Objective: To assess the effectiveness of the PAST (Pre-hospital Acute Stroke Triage) protocol in reducing pre-hospital and emergency department (ED) delays to patients receiving organised acute stroke care, thereby increasing access to thrombolytic therapy.

Design: Prospective cohort study using historical controls.

Setting: Hunter Region of New South Wales, September 2005 to March 2006  (pre-intervention) and September 2006 to March 2007 (post-intervention).

Participants: Consecutive patients presenting with acute stroke to a regional, tertiary referral hospital.

Intervention: PAST protocol, comprising a pre-hospital stroke assessment tool for ambulance officers, an ambulance protocol for hospital bypass for potentially thrombolysis-eligible patients, and pre-hospital notification of the acute stroke team.

Main outcome measures: Proportion of patients who received intravenous tissue plasminogen activator (tPA), process of care time points (symptom onset to ED arrival, ED arrival to tPA treatment, and ED transit time), and clinical outcomes of patients treated with tPA.

Results: The proportion of ischaemic stroke patients treated with tPA increased from 4.7% (pre-intervention) to 21.4% (post-intervention) (P < 0.001). Time point outcomes also improved, with a reduction in median times from symptom onset to ED arrival from 150 to 90.5 min (P = 0.004) and from ED arrival to stroke unit admission from 361 to 232.5 minutes (P < 0.001). Of those treated with tPA, 43% had minimal or no disability at 3 months.

Conclusions: Organised pre-hospital and ED acute stroke care increases patient access to tPA treatment, which is proven to reduce stroke-related disability.

Care in a stroke unit improves long-term outcomes for stroke patients, underpinning the enhanced organisation of stroke services now underway across Australia.1,2 An important component of organised acute stroke care is thrombolytic therapy with intravenous tissue plasminogen activator (tPA),2,3 which was licensed for use in Australia in 2003. This highly cost-effective therapy4-6 substantially reduces major disability when used in an expert setting.7,8

Only a small proportion of stroke patients currently receive thrombolytic therapy.9-11 A major factor limiting patient access is that few arrive at expert stroke centres within the narrow 3-hour treatment window. Patient access to tPA could potentially be improved by extending organised stroke care through a cooperative system that crosses the traditional clinical and administrative boundaries of the acute stroke unit, emergency department (ED) and pre-hospital sector.

Where extended organised acute care has been successfully implemented, up to 20% of patients with ischaemic stroke are treated with tPA.12-14 Collaboration with ambulance services is recognised as a key to decreasing the time to presentation for patients with acute stroke. Pre-hospital stroke screening tools, such as the Los Angeles Prehospital Stroke Screen (LAPSS)15 and the Face Arm Speech Test (FAST),16 aid this process. These tools have acceptable diagnostic accuracy in the field and are important components of protocols for pre-hospital stroke care.

This study tested the effectiveness of an acute stroke care intervention developed in the Hunter Region of New South Wales — the Pre-hospital Acute Stroke Triage (PAST) protocol. This comprises a pre-hospital stroke assessment tool, an ambulance hospital-bypass protocol for thrombolysis-eligible patients outside the primary catchment area of the John Hunter Hospital, and the pre-notification and rapid deployment of the hospital’s multidisciplinary stroke team. The PAST protocol was designed to reduce pre-hospital and ED delays to tPA treatment, and to streamline the initial management of patients by the existing acute stroke team.

Methods
Development of the PAST protocol

John Hunter Hospital, Newcastle, is the principal tertiary referral hospital for the NSW Hunter Region, serving a population of about one million people. The hospital’s acute stroke team comprises an on-call stroke neurologist and an acute stroke nurse, as well as ED medical and nursing staff, and radiology staff.

Development of the protocol was coordinated by a steering committee comprising members of the ED, the acute stroke team and the NSW Ambulance Service. It involved collation and review of baseline stroke care performance data from the hospital’s acute stroke database for the calendar years 2005 and 2006, with a specific focus on factors affecting tPA eligibility. Major system barriers to organised care and tPA therapy were identified as:

  • lack of awareness among ambulance officers of the evidence and requirements for rapid access to organised acute stroke care;

  • delivery of potentially thrombolysis-eligible patients to hospitals within the Hunter Region not equipped to provide a stroke thrombolysis service; and

  • delays in acute stroke team notification on arrival of potentially thrombolysis-eligible stroke patients in the ED.

Components of the PAST protocol

To resolve these problems, the steering committee developed firstly a pre-hospital stroke assessment tool for ambulance officers, and secondly a pre-hospital notification system.

The pre-hospital stroke assessment tool was adapted from the United Kingdom FAST tool,16 to complement the National Stroke Foundation FAST community awareness campaign and existing assessment tools used by NSW ambulance officers. The local GAS-T tool has four elements:

  • G = glucose in the “normal” range (4–17 mmol/L);

  • A = arm drift, grip strength;

  • S = speech disturbance; and

  • T = time since symptom onset (Box 1).

An important difference from the UK tool is the replacement of the more difficult facial asymmetry test, “F”, with a simple finger-prick glucose test, “G”. Hyperglycaemia is a relative contraindication to tPA, being associated with poor outcomes and higher rates of haemorrhagic transformation,17 while hypoglycaemia is a known stroke mimic and may have led to reduced diagnostic accuracy in the field. “T” was added to the tool to emphasise the importance of the 2-hour time window. Although tPA is licensed for treatment of patients with ischaemic stroke within 3 hours of symptom onset, the third hour was allocated to in-hospital pretreatment procedures, such as patient assessment, imaging and gaining patient assent.

The cost of setting up the PAST protocol was minimal as the acute stroke team was already in place. Members of this team provided after-hours training for ambulance officers, and ambulance educators incorporated lectures on stroke and the GAS-T tool into in-service sessions. Pocket cards outlining the GAS-T tool were funded by the NSW Ambulance Service Northern Division and distributed to all Hunter Region ambulance officers.

In addition, a pre-hospital notification system was set up, whereby the ambulance operations centre used Short Message Service (SMS) messaging to notify the on-call stroke neurologist when a patient met the GAS-T criteria. This allowed the neurologist to check the mandatory criteria before giving approval for the ambulance to bypass other regional hospitals when the patient was outside the primary catchment area of John Hunter Hospital. It also enabled rapid deployment of the acute stroke team to the ED to meet the ambulance at triage.

Evaluation of the PAST protocol

The study was a prospective cohort study using historical controls from the same hospital in the corresponding period 1 year earlier. The study population comprised all patients with an initial diagnosis of acute stroke presenting to John Hunter Hospital. The intervention (PAST) group were those patients who presented to the hospital in the 6-month period from September 2006 to March 2007, immediately after implementation of the PAST protocol. The control group were those patients who presented in the corresponding period a year earlier, September 2005 to March 2006. Apart from the PAST protocol, the operating policies and procedures used by the acute stroke team were standard and did not alter over the period of the PAST protocol evaluation.

Outcome measures

The primary outcome measure was the proportion of ischaemic stroke patients who received intravenous tPA therapy in the PAST versus the control group.

Secondary outcome measures were process of care measures, including time from symptom onset to arrival at hospital (onset to door); time from arrival at hospital to commencement of tPA (door to needle); and transit time in the ED (door to admission to the ward, defined as the acute stroke unit). For the time-process measures, we compared patients with a definite symptom onset time within 24 hours of presentation to hospital in the PAST and control groups.

Tertiary outcome measures were based on clinical outcome at 3 months measured by the modified Rankin score (a validated disability measure where 0–1 = excellent outcome; 2 = functional independence; 3 =moderate disability; and 4–5 = major disability).18,19 Outcomes were compared between patients treated with tPA in the PAST group, and patients in the NINDS (National Institute of Neurological Disorders and Stroke) tPA trial7 and the SITS (Safe Implementation of Thrombolysis in Stroke) tPA registry.20

Statistical analyses

Statistical analyses were performed using Stata version 9 (Stata Corp, College Station, Tex, USA). Continuous data were analysed using the Student t test when the assumption of normality appeared appropriate, and the Wilcoxon rank sum test when we believed this assumption was invalid. Categorical data were analysed using χ2 tests or the Fisher exact test when the expected count in table cells was too low. P values less than 0.05 were considered statistically significant.

The Hunter New England Human Research Ethics Committee considered PAST as a quality improvement project, and individual patient consent was thus not required.

Results

During the 6-month PAST protocol period, 232 patients presented to the John Hunter Hospital ED with an initial diagnosis of stroke, and 140 of these (60%) had a final discharge diagnosis of ischaemic stroke (Box 2). Of the 232 patients, 122 (53%) had a defined onset time within the previous 24 hours, and 51 of the 232 were delivered to John Hunter Hospital using the PAST protocol.

In the 6-month control period, 205 patients presented to the John Hunter Hospital ED with an initial diagnosis of stroke, and 107 (52%) had a final discharge diagnosis of ischaemic stroke (Box 2). Of the 205 patients, 61 (30%) had a defined onset time within the previous 24 hours.

Access to tPA therapy

There was a statistically significant increase in the proportion of ischaemic stroke patients who received intravenous tPA therapy in the PAST group compared with the control group: 21.4% (95% CI, 14.6%–28.2%) versus 4.7% (95% CI, 1.5%–10.6%); P < 0.001) (Box 3). Expressed as a percentage of all patients presenting to the ED with an initial diagnosis of stroke, 12.9% (95% CI, 8.6%–17.2%) received tPA during the PAST period compared with 2.4% (95% CI, 0.8%–5.6%) during the control period (P < 0.001).

Among the 51 patients in the intervention period who met the PAST protocol criteria, 39 had a discharge diagnosis of ischaemic stroke, and 24 of the 39 were treated with tPA. A further six who did not meet the PAST protocol criteria for pre-notification received tPA, resulting in a total of 30 patients in the PAST period receiving intravenous tPA.

Among the 15 ischaemic stroke patients in the PAST group who did not receive tPA, stroke severity was considered too mild, or the deficits were rapidly resolving in six, another six had relative or absolute contraindications to tPA therapy, and the acute stroke team determined an earlier symptom onset time, outside the thrombolysis time window, for the remaining three.

In the control group, 61 patients (30%) arrived at the John Hunter Hospital ED within 24 hours of symptom onset, 38 of whom (62%) had a discharge diagnosis of ischaemic stroke. Five of these 38 received thrombolytic therapy.

Process of care indicators

Process of care measures are shown in Box 4. The median time from symptom onset to hospital arrival was reduced by 1 hour in the PAST group compared with the control group (90.5 v 150 min; P = 0.004). The median ED transit time was also reduced in the PAST group (232.5 v 361 minutes in the control group; P < 0.001). Door to needle times among those who received tPA were similar in the two groups (91.5 v 89 minutes; P = 0.40), but very few patients in the control group (five) received tPA.

Clinical outcomes after tPA therapy

Three-month outcomes for patients treated with tPA during the PAST period compared favourably with those for tPA-treated patients in the benchmark NINDS tPA trial,7 the SITS international phase IV tPA registry,20 and published Australian audits of tPA implementation8,21 (Box 5). Baseline stroke severity measured by the National Institutes of Health Stroke Scale (NIHSS)7 was worse in our cohort than comparators. Despite this, 43% of our tPA group had minimal or no disability at 3 months, which is at least equivalent to national and international benchmarks.19,22

Discussion

Audits of tPA use in Australia currently indicate that only 0.9% of all ischaemic stroke patients receive this treatment.9 Given the international evidence that changes in the process of care can substantially increase tPA use,2,23,24 and given the cost effectiveness of tPA therapy,4 there is a clear need to develop support systems and care models to help stroke clinicians in Australia redesign pre-hospital and emergency care systems for acute stroke. Published pre-hospital stroke care protocols have tended to focus on single components of the process of care, such as assessment,25 ED triage,26,27 or in-hospital fast-track protocols.28 PAST is the first Australian stroke protocol that covers both pre-hospital assessment and ED care.

We found that the PAST protocol reduced pre-hospital and ED delays to treatment and significantly increased the proportion of patients treated with intravenous tPA. This partly reflects the substantial reduction in time from symptom onset to hospital arrival during the implementation period. The proportion of patients who arrived at our centre within 2 hours of symptom onset was similar to the proportion who arrived within 3 hours of symptom onset at another Australian centre that had no pre-hospital stroke ambulance protocol in place.23 An additional major benefit of the PAST protocol was the substantial reduction in ED transit time, probably reflecting earlier mobilisation of the stroke team, allowing advance discussions with hospital bed managers.

Our study had potential limitations, particularly the use of historical controls (albeit prospectively collected) and the non-randomised design. This may have resulted in a higher proportion of more severe strokes in the PAST group (Box 2), which may have contributed to the higher rate of early presentation in the PAST period, as these particular strokes may be more readily diagnosed by ambulance officers in the field. Additionally, the retrieval of patients from outside the usual hospital catchment area may have increased the proportion of patients receiving thrombolysis. However, this was a specific aim of the PAST protocol. Indeed, as in most Australian regional areas, these patients would not have had access to thrombolytic therapy before implementation of PAST. While the PAST protocol worked well in the Hunter Region, its geography and systems differ from those in larger metropolitan areas of Australia, where implementation of a similar protocol may be more challenging.

Most importantly, the substantial increase in the proportion of patients treated with tPA during the PAST period is likely to have an impact on stroke-related disability in our region. Using a number needed to treat (NNT) of eight to prevent one case of major disability,7 and with an absolute increase of 25 patients treated during the PAST period, we estimate that over the 6-month period, the protocol prevented three patients from requiring nursing home care. Not only is this meaningful at an individual patient level, but the impact of the protocol being implemented throughout all Australian metropolitan and large regional areas could be substantial. For example, assuming implementation of PAST resulted in a modest increase of 5% in patients treated with thrombolysis Australia-wide (compared with the 16% increase seen in our study), then about 2500 more patients would be treated per annum. Using the same NNT, 312 patients would be saved from major disability, with a cost saving of $31.2 million (from reduced need for rehabilitation and nursing home care) in the first 12 months.4

The prioritisation and preferential transport by ambulance services of patients with suspected stroke to centres with stroke units conforms with the recommendations of the National Strategic Improvement Framework for Heart, Stroke and Vascular Disease28 and the 2007 National Stroke Foundation guidelines.2 While a significant commitment on the part of health care providers would be needed, implementation of “fast-track” protocols such as PAST, supported by well organised, hospital-based stroke care nationwide, would have a substantial impact on stroke-related disability, as well as the resultant burdens and costs to the individual and community. Relatively few therapies have an absolute cost saving. When highly effective therapies are available for a disease of such enormous community impact as stroke, directing efforts and resources towards redesign of pre-hospital and acute stroke care systems appears both desirable and justified.

1 Pre-hospital Acute Stroke Triage (PAST) protocol

2 Patient characteristics, by treatment group

Control group (n = 205)

PAST group (n = 232)


Male

104 (51%)

120 (52%)

Mean age in years (range)

69 (21–100)

71 (24–98)

Ischaemic stroke

Total anterior circulation infarct

31 (15%)

53 (23%)

Partial anterior circulation infarct

37 (18%)

47 (20%)

Lacunar infarct

24 (12%)

23 (10%)

Posterior circulation infarct

15 (7%)

17 (7%)

Intracerebral haemorrhage

37 (18%)

29 (13%)

Transient ischaemic attack

45 (22%)

37 (16%)

Non-stroke

16 (8%)

26 (11%)

Onset time available

64 (31%)

122 (53%)

Onset within previous 24 h (% of patients with data available)

61 (95%)

122 (100%)

Presentation within 2 h of onset (% of patients with data available)

26 (41%)

68 (56%)


PAST = Pre-hospital Acute Stroke Triage.

3 Number of patients with ischaemic stroke and number who received tPA, by treatment group

Control group (n = 205)

PAST group (n = 232)

P


No. with ischaemic stroke

107 (52.1%)

140 (60.3%)

0.12

No. who received tPA among

All patients presenting with stroke

5 (2.4%)

30 (12.9%)

< 0.001

Ischaemic stroke patients

5 (4.7%)

30 (21.4%)

< 0.001


tPA = tissue plasminogen activator. PAST = Pre-hospital Acute Stroke Triage.

4 Process measures for patients with a defined symptom onset time within 24 hours of presentation to hospital and for patients who received tPA (values are median and IQR)

Control group

PAST group

P*


Sample size

All patients

61

122

Recipients of tPA

5

30

Onset to door time (min)

All patients

150 (93–339)

90.5 (63–185)

0.004

Recipients of tPA

98 (85–101)

63.5 (52–89)

0.14

Door to ward time (min)

All patients

361 (204–569)

232.5 (154–388)

< 0.001

Recipients of tPA

184 (120–204)

121 (77–179)

0.20

Door to needle time (min)

Recipients of tPA

89 (85–160)

91.5 (70–100)

0.40


IQR = interquartile range. PAST = Pre-hospital Acute Stroke Triage. tPA = tissue plasminogen activator. * Wilcoxon rank sum test.

5 Distribution of patient outcomes at 3 months after stroke, based on modified Rankin scores, in our study (PAST protocol) and other Australian and international studies


NINDS = National Institute of Neurological Disorders and Stroke tPA trial.7 SITS = Safe Implementation of Thrombolysis in Stroke tPA registry.20 * Values above columns are the median baseline NIHSS (National Institutes of Health Stroke Scale) scores for each cohort.

Received 9 January 2008, accepted 19 June 2008

  • Debbie A Quain1,2
  • Mark W Parsons1,2,3
  • Allan R Loudfoot4
  • Neil J Spratt1,3
  • Malcolm K Evans1
  • Michelle L Russell1
  • Angela T Royan1
  • Andrea G Moore1
  • Ferdinand Miteff1,2
  • Carolyn J Hullick2
  • John Attia3,1
  • Patrick McElduff1,3
  • Christopher R Levi1,2

  • 1 Hunter Medical Research Institute, Newcastle, NSW.
  • 2 John Hunter Hospital, Newcastle, NSW.
  • 3 University of Newcastle, Newcastle, NSW.
  • 4 Northern Ambulance Service of NSW, Newcastle, NSW.


Competing interests:

Christopher Levi, Mark Parsons and Neil Spratt have received speaker fees and educational grants from Boehringer Ingelheim.

  • 1. Cadilhac DA, Lalor EE, Pearce DC, et al. Access to stroke care units in Australian public hospitals: facts and temporal progress. Intern Med J 2006; 36: 700-704.
  • 2. Crimmins D, Bladin C, Lalor E. Clinical guidelines for acute stroke management 2007. Melbourne: National Stroke Foundation, 2007.
  • 3. Hack W, Kaste M, Bogousslavsky J, et al. European Stroke Initiative Recommendations for Stroke Management — update 2003. Cerebrovasc Dis 2003; 16: 311-337.
  • 4. Moodie ML, Carter R, Mihalopoulos C, et al. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke 2004; 35: 1041-1046.
  • 5. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998; 50: 883-890.
  • 6. Sandercock P, Berge E, Dennis M, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004; 35: 1490-1497.
  • 7. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
  • 8. Bray JE, Coughlan K, Bladin C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J 2006; 36: 483-488.
  • 9. Randahawa D. National stroke audit organisational report acute services 2007. Melbourne: National Stroke Foundation, 2007: 6-8.
  • 10. Qureshi AI, Fareed K, Nasar A, et al. Thrombolysis for ischemic stroke in the United States: data from national hospital discharge survey 1999–2001. Neurosurgery 2005; 57: 647-654.
  • 11. McCormick M, Baird M, Bone I, Muir K. Implementation of stroke thrombolysis in the United Kingdom. Glasgow: University of Glasgow, 2006.
  • 12. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001; 58: 2009-2013.
  • 13. Schmulling S, Grond M, Rudolf J, Heiss W. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 2000; 31: 1552-1554.
  • 14. Wojner-Alexandrov AW, Rodriguez D, Persse D, et al. Houston paramedic and emergency stroke treatment and outcomes study (HoPSTO). Stroke 2005; 36: 1512-1518.
  • 15. Kidwell CS, Starkman S, Eckstein M, et al. Identifying stroke in the field. Prospective validation of the Los Angeles prehospital stroke screen (LAPSS). Stroke 2000; 31: 71-76.
  • 16. Harbison J, Hossain O, Jenkinson D, et al. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003; 34: 71-76.
  • 17. Weir CJ, Murray GD, Dyker AG, et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ 1997; 314: 1303-1306.
  • 18. Bonita R, Beaglehole R. Modification of Rankin Scale: recovery of motor function after stroke. Stroke 1988; 19: 1497-1500.
  • 19. Rankin J. Cerebral vascular accidents in patients over the age of 60. I. General considerations. Scott Med J 1957; 2: 127-136.
  • 20. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
  • 21. Szoeke CEI, Parsons MW, Butcher KS, et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-328. <MJA full text>
  • 22. Batmanian JJ, Lam M, Matthews C, et al. A protocol-driven model for the rapid initiation of stroke thrombolysis in the emergency department. Med J Aust 2007; 187: 567-570. <MJA full text>
  • 23. Lindsberg PJ, Happola O, Kallela M, et al. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology 2006; 67: 334-336.
  • 24. Bray JE, Martin J, Cooper G, et al. An interventional study to improve paramedic diagnosis of stroke. Prehosp Emerg Care 2005; 9: 297-302.
  • 25. Morris DL, Rosamond W, Madden K, et al. Prehospital and emergency department delays after acute stroke: the Genentech Stroke Presentation Survey. Stroke 2000; 31: 2585-2590.
  • 26. Rajajee V, Saver J. Prehospital care of the acute stroke patient. Tech Vasc Interv Radiol 2005; 8: 74-80.
  • 27. Tilley BC, Lyden PD, Brott TG, et al. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol 1997; 54: 1466-1474.
  • 28. National Health Priority Action Council. National Service Improvement Framework for Heart, Stroke, and Vascular Disease. Canberra: Australian Government Department of Health and Ageing, 2006: 115.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.